Landmark current use
immunotherapyformelanoma.com
Evidence snapshot
Patients, caregivers, clinicians, and research-aware readers.
Educational only. Treatment depends on cancer subtype, stage, biomarkers, prior therapy, and local approvals.
Patient language access
Melanoma first, then the full page.
Choose a language to open this melanoma immunotherapy page through Google Translate. Automated translation is for orientation only; clinical decisions still need an oncologist, interpreter, and local treatment advice.
About this cancer
Quick clinical overview
Melanoma is less common than basal or squamous skin cancer but is more likely to spread. It occurs across adult ages and is linked strongly with ultraviolet exposure and phenotype.
Types include superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentiginous melanoma, mucosal melanoma, uveal melanoma, and metastatic melanoma.
Risk factors include UV exposure, sunburns, tanning beds, fair skin, many or atypical moles, family history, inherited variants such as CDKN2A in some families, immune suppression, and prior melanoma.
Symptoms include a changing mole, asymmetric or irregular lesion, multiple colors, bleeding, itching, a new dark spot, a nonhealing lesion, swollen lymph nodes, or symptoms from metastases.
Diagnosis uses skin examination, dermoscopy, excisional biopsy when possible, pathology, sentinel lymph node biopsy in selected cases, BRAF testing, imaging for higher-stage disease, and ongoing skin surveillance.
Treatment includes surgical excision, sentinel node management, immunotherapy, BRAF/MEK targeted therapy for selected tumors, radiation in selected cases, TIL therapy in selected advanced disease settings, and trials.
Condition-specific visual cues
Scans, pathology, and testing imagery
Stage 4 and metastatic disease
Advanced cancer context
Stage 4 melanoma can spread to lymph nodes, skin/subcutaneous tissue, lung, liver, brain, bone, gastrointestinal tract, or other organs.
PET/CT or CT, brain MRI, biopsy, BRAF testing, LDH, and monitoring for immune response patterns and immune-related adverse events are common.
Metastatic melanoma is one of the landmark checkpoint immunotherapy indications; PD-1 therapy, CTLA-4/PD-1 combinations, TIL therapy, BRAF/MEK therapy for BRAF-mutant disease, and trials may all be relevant.
Ask the oncology team whether stage 4 treatment is aiming for remission, long-term control, symptom relief, trial entry, or a sequence of several systemic treatments.
Treatment sequence
Where immunotherapy usually fits
Immunotherapy is often considered after surgery, radiation, chemotherapy, hormone therapy, or targeted therapy, especially when cancer is recurrent, metastatic, or hard to control. But that is not a fixed rule. In some cancers, immunotherapy is already used first-line, before surgery, after surgery to reduce recurrence risk, or early for biomarker-selected tumors. The right timing depends on the cancer type, stage, biomarkers, prior treatments, symptoms, urgency, performance status, and clinical trial availability.
This site separates current standard use from research-only use. Patients should ask their oncology team: Is immunotherapy approved for my exact cancer and stage, is it biomarker-dependent, and is there a trial that should be considered before or after conventional treatment?
Cost and access
Coverage changes frequently
Immunotherapy can be very expensive, especially CAR T-cell therapy, personalised vaccines, and newer checkpoint inhibitor combinations. This section is a current-status indicator only, not a guarantee of payment. A medicine may be approved but not funded, funded only for one cancer stage or biomarker group, or covered only after other treatments have been tried.
Always check the latest local formulary, insurer pre-authorisation rules, trial protocol, and the exact wording of the indication. Funding can change quickly when a new drug, biomarker group, line of therapy, or price agreement is approved.
The treating oncologist, cancer center pharmacist, clinical trials unit, social worker, or hospital financial navigator is usually the best source for current local access, insurer appeals, compassionate access, manufacturer programs, and whether a trial may cover the study drug.
United States
Government / public: Medicare/Medicaid may cover FDA-approved and medically accepted cancer immunotherapies when medical-necessity and site-of-care rules are met. Medicare has a national coverage determination for FDA-approved or compendia-supported autologous CAR T-cell therapy at REMS-enrolled facilities; non-FDA-approved CAR T is non-covered outside qualifying trial/routine-cost rules.
Private insurance: Private insurance may cover approved uses, but prior authorization, step therapy, network rules, specialty-center rules, copays, coinsurance, and denial appeals are common.
Australia
Government / public: PBS may subsidise listed immunotherapy medicines for specific cancer indications and restrictions; Medicare/MBS and public hospitals may cover services around treatment. Some cellular therapies are funded through specialised public hospital pathways rather than ordinary pharmacy dispensing.
Private insurance: Private health insurance may help with hospital and specialist costs, but unfunded cancer drugs or off-label immunotherapy may still be out-of-pocket unless specifically approved.
United Kingdom
Government / public: NHS access usually depends on NICE technology appraisal recommendations, Cancer Drugs Fund arrangements, or national commissioning rules for the exact medicine and indication.
Private insurance: Private insurance may cover approved oncology drugs if included in the policy and pre-authorised; off-label or trial-only use is often excluded.
Canada
Government / public: After Health Canada approval, public drug programs and cancer agencies decide reimbursement. CDA-AMC gives non-binding reimbursement recommendations; provinces and territories make final decisions, so access varies.
Private insurance: Private plans may cover some outpatient drugs, but many hospital-administered cancer drugs are handled through provincial cancer systems. Coverage is highly plan- and province-specific.
New Zealand
Government / public: Pharmac funding determines access for many medicines. A drug can be clinically useful or approved elsewhere but not publicly funded for a given New Zealand indication.
Private insurance: Private insurance or self-funding may help in selected cases, but high-cost immunotherapy can remain unaffordable without public funding or a trial.
European Union / EEA
Government / public: EMA marketing authorisation is not the same as reimbursement. Each country makes health-technology assessment, pricing, and reimbursement decisions through national systems.
Private insurance: Private cover varies widely by country and policy. Approved but not reimbursed indications may still require self-pay, compassionate access, or trial access.
Other countries
Government / public: Coverage varies greatly. Some countries fund only a limited set of immunotherapies; others require self-pay, charity access, manufacturer access programs, or referral to major cancer centers.
Private insurance: Insurance may cover approved cancer medicines, but high-cost CAR T, checkpoint inhibitors, vaccines, or off-label combinations often need pre-approval and may be excluded.
Approved and commonly used context
Current immunotherapy use
- PD-1 inhibitors and CTLA-4/PD-1 combinations are central options in selected advanced melanoma.
- Immunotherapy can be used after surgery or before surgery in selected high-risk melanoma settings.
- BRAF/MEK targeted therapy remains important for tumors with BRAF V600 mutations.
What to watch next
Research direction
- Neoadjuvant treatment, response-adapted surgery, cellular therapies, melanoma vaccines, and better toxicity prediction.
- Sequencing immunotherapy and BRAF/MEK therapy in BRAF-mutant melanoma.
BRAF V600
NRAS
KIT
PD-L1 research
stage III/IV
brain metastases
Live trial radar
ClinicalTrials.gov links
Paper and source trail